Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor*

Background: TAZ functions as a co-activator by up-regulating downstream transcriptional targets. Results: TAZ can negatively regulate transcription of many genes such as ΔNp63 through TEAD transcription factor. Conclusion: TAZ can also function as a transcriptional co-repressor. Significance: Our findings open a new avenue for TAZ function in cancer. Transcriptional co-activator with a PDZ binding domain (TAZ) is a WW domain-containing transcriptional co-activator and a core component of an emerging Hippo signaling pathway that regulates organ size, tumorigenesis, metastasis, and drug resistance. TAZ regulates these biological functions by up-regulating downstream cellular genes through transactivation of transcription factors such as TEAD and TTF1. To understand the molecular mechanisms underlying TAZ-induced tumorigenesis, we have recently performed a gene expression profile analysis by overexpressing TAZ in mammary cells. In addition to the TAZ-up-regulated genes that were confirmed in our previous studies, we identified a large number of cellular genes that were down-regulated by TAZ. In this study, we have confirmed these down-regulated genes (including cytokines, chemokines, and p53 gene family members) as bona fide downstream transcriptional targets of TAZ. By using human breast and lung epithelial cells, we have further characterized ΔNp63, a p53 gene family member, and shown that TAZ suppresses ΔNp63 mRNA, protein expression, and promoter activity through interaction with the transcription factor TEAD. We also show that TEAD can inhibit ΔNp63 promoter activity and that TAZ can directly interact with ΔNp63 promoter-containing TEAD binding sites. Finally, we provide functional evidence that down-regulation of ΔNp63 by TAZ may play a role in regulating cell migration. Altogether, this study provides novel evidence that the Hippo component TAZ can function as a co-repressor and regulate biological functions by negatively regulating downstream cellular genes.

The Hippo pathway was originally discovered in Drosophila as an evolutionarily conserved tumor suppressor pathway that acts as a key regulator of organ size control (1,2). This signaling pathway has been shown to control many biological functions such as cell proliferation, apoptosis, cell-cell contact inhibition, stem cell self-renewal, and tissue regeneration (2)(3)(4)(5)(6)(7)(8)(9)(10). In mammals, cell-cell contact or increased actin polymerization can activate mammalian sterile-20-like kinase 1/2, which subsequently activates adaptor proteins Mob1A/1B and scaffold protein salvador (Sav1) to promote the phosphorylation and activation of large tumor suppressor 1/2 kinases. In turn, large tumor suppressor 1/2 phosphorylate downstream transcriptional co-activators transcriptional co-activator with a PDZ binding domain (TAZ) 5 and its paralog yes-associated protein (YAP) to promote their cytoplasmic retention and subsequent degradation (11)(12)(13)(14). Conversely, dephosphorylated YAP and TAZ are able to enter the nucleus where they interact with multiple transcription factors and exert high transactivation activity.
TAZ is a widely characterized oncogene that is overexpressed or dysregulated in several cancer types including breast (15,16), lung (17,18), colorectal (19), and thyroid (20). It is proposed as a major regulator of cell proliferation, cell migration and invasion, epithelial-mesenchymal transition (EMT), human embryonic stem cell renewal, and drug resistance (21)(22)(23)(24)(25)(26)(27). Within the N terminus of TAZ lies a TEAD binding domain (TBD) responsible for the interaction with the TEAD family of transcription factors. Mounting evidence over the years has supported TEAD family members as one of the most common binding partners of TAZ; they play crucial roles in mediating many TAZ functions including cellular growth, proliferation, and oncogenic transformation (28 -31). The mechanisms underlying TAZ-mediated transcriptional activation of downstream genes through its interaction with transcription factors have been often studied and observed by many research groups. However, there has been little interest in elucidating novel tar-gets negatively regulated by TAZ and addressing their molecular mechanisms and functional implications in tumorigenesis.
In this study, we have identified ⌬Np63, a member of the p53 tumor suppressor family, as a significantly down-regulated target in TAZ-overexpressing breast and lung epithelial cells. Moreover, we show that TAZ-induced repression of ⌬Np63 transcription is mediated by the TEAD family of transcription factors and that reintroduction of ⌬Np63 into TAZ-overexpressing cells partially rescues TAZ-induced cell migration. Together, our findings provide the first evidence that TAZ can directly negatively regulate cellular gene transcription by interacting with TEAD transcription factor.
Lentiviral Production, Infection, and Establishment of Cell Lines with Stable Overexpression of Cellular Genes-Lentiviral production, purification, titration, and infection of overexpressing constructs were performed as described (11). Generation of ⌬Np63-overexpressing stable cell lines was performed by infecting TAZ-overexpressing MCF10A cells with lentivirus expressing Dox-inducible ⌬Np63 (pTRIPZ vector) at a multiplicity of infection of 2. Generation of stable cell lines with overexpression of TEAD binding mutants of TAZ was performed by infecting TAZ-low MCF10A cells with lentivirus expressing TAZ-F52A/F53A-HA (WPI vector) or Dox-inducible TAZ-S89A-F52A/F53A-HA at a multiplicity of infection of 2. Cells were selected 48 h postinfection using 1 g/ml puromycin.
Microarray and Data Analysis-Gene expression profile analysis by microarray and data analysis were as described (32).
Reagents, Antibodies, Western Blotting, and Co-immunoprecipitation-Trichostatin A and UNC0631 were purchased from Sigma. The mouse monoclonal antibodies used in this study were obtained from the following companies: anti-TAZ from BD Pharmingen; anti-p63 (4A4), anti-vestigial-like protein 4 (VGLL4), and anti-FLAG (M2) from Sigma-Aldrich; anti-TEAD (TEF-1) from Abcam; and anti-HA (F7) from Santa Cruz Biotechnology. Anti-histone acetylation component antibodies were obtained from Cell Signaling Technology. Protein extraction, Western blot analyses, and co-immunoprecipitation were performed as described (11).
RNA Isolation and Quantitative Reverse Transcription-PCR (qRT-PCR)-Cells were grown to about 70 -90% confluence. RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. RNA quantitation and quality were assessed by spectrophotometry and RNase-free gel electrophoresis. qRT-PCR analyses were performed in duplicates of 200 ng/l RNA/sample/reaction with 200 nM genespecific forward and reverse primers (Table 1) using the Super-Script III Platinum SYBR Green One-Step qRT-PCR kit (Invitrogen) and the Applied Biosystems ViiA 7 Real-Time PCR System. 18S ribosomal RNA (rRNA) expression was used as an internal control. mRNA expression levels were calculated as described (11) and are shown as -fold change.
Chromatin Immunoprecipitation (ChIP) Assay-A ChIP-IT Express enzymatic kit (Active Motif) was used for ChIP analysis of TAZ-S89A and ⌬Np63 promoter interaction. MCF10A cells expressing WPI or TAZ-S89A were grown to 70 -80% confluence on 150-mm dishes. Cells were treated with 1% formaldehyde, lysed, harvested, and homogenized using a Dounce homogenizer according to the manufacturer's protocol. DNA was enzymatically sheared, and the fragmented chromatin was incubated with 2 g of mouse anti-HA (F7) monoclonal anti-body. Chromatin was eluted, reverse cross-linked, and treated with Proteinase K. Amplification of the ⌬Np63 promoter was performed by PCR using the following primers: (5Ј-ATGGTA-CCGTCTGTCTCCTGGGTTTG-3Ј (sense) and 5Ј-GTGCA-CTTTCTTATGAAAGAGAC-3Ј (antisense)). The PCR products were run on a 3% ethidium bromide-agarose gel and visualized under UV light using the Gel Doc system.
Statistical Analysis-Significant differences were analyzed by Student's t test, and differences in mRNA levels between MCF10A-TAZ and its mutants and in promoter activities were calculated using analysis of variance tests. A p value Ͻ0.05 was regarded as statistically significant.

Results
Identification and Validation of Target Genes Negatively Regulated by TAZ-To identify downstream genes mediating TAZ function, we performed a 44,000 whole human genome microarray profiling (32) using RNAs from MCF10A stably expressing WPI empty vector control (MCF10A-WPI) or wildtype TAZ (MCF10A-TAZ). Enhanced TAZ mRNA and protein expression levels were confirmed by qRT-PCR and Western blotting (Fig. 1, A and B). Although 390 genes were up-regulated by TAZ (32), surprisingly, about 328 cellular genes were also found to be down-regulated by TAZ ( Fig. 1C and supplemental Table S1). Based on their functional relevance in tumorigenesis, we confirmed several target genes from our DNA microarray results using real time qRT-PCR. Interestingly, we identified several proinflammatory cytokines and chemokines including IL1␣/␤, IL6, IL8, CXCL1/2/3, and BMP2 as well as p63 isoforms ⌬Np63 and TAp63 as significantly down-regulated (1.5-10 Ϯ 0 -0.05-fold) targets in MCF10A-TAZ cells (Fig. 1D). Among these, proinflammatory cytokines IL1␣ and IL1␤ showed the most significant decrease in their relative mRNA expression, suggesting a possible involvement of TAZ in immune and inflammatory responses. Surprisingly as well, the p53 family members TAp63 and its N-terminal truncated form ⌬Np63 showed an important TAZ-induced suppression in mRNA expression levels. Because p63 has been previously suggested as a marker of epithelial breast carcinoma and plays important roles in tumorigenesis and metastasis (33,34), we sought to elucidate the molecular mechanisms and functional implications of TAZ-mediated repression of p63.
⌬Np63 Is a Novel Down-regulated Target of TAZ-To further confirm TAZ-mediated suppression of p63 in MCF10A cells, we performed protein analysis using Western blotting. Protein lysates from MCF10A-WPI and MCF10-TAZ cells were analyzed together with MCF-7 p63 negative control and COS7 cells transfected with TAp63-FLAG and ⌬Np63-FLAG plasmids. We identified ⌬Np63 rather than TAp63 as the p63 protein isoform predominantly suppressed by TAZ in MCF10A-TAZ cells ( Fig. 2A). Similarly, ⌬Np63 protein expression was highly decreased in MCF10A cells after transient induction of wildtype TAZ (TAZ-WT) or constitutively active TAZ (TAZ-S89A) by Dox (Fig. 2B), suggesting that suppression of ⌬Np63 by TAZ is not caused by viral infection or puromycin selection during establishment of stable lines. As expected, inducible expression of TAZ-S89A displayed a stronger effect on ⌬Np63 repression compared with TAZ-WT. To characterize ⌬Np63 as a bona fide down-regulated target gene of TAZ in other cell type, we analyzed ⌬Np63 protein expression levels in HBE135 human bronchial epithelial lung cells containing inducible expression of TAZ-S89A (Fig. 2C). Interestingly, ⌬Np63 expression was also repressed in HBE135 cells after TAZ induction, similar to the effect observed in MCF10A cells. Furthermore, we performed transient TAZ knockdown using siRNAs (siTAZ) in HCC38 human epithelial breast cancer cells and A549 human lung adenocarcinoma cells that expressed high levels of TAZ (35). 6 6 X. Yang, unpublished data.    ⌬Np63 protein levels were significantly increased after TAZ was knocked down in both cell lines (Fig. 2D). Finally, we sought to elucidate the effects of TAZ overexpression on ⌬Np63 promoter activity using the Dual-Luciferase assay. The promoter region of ⌬Np63 was cloned from MCF10A genomic DNA into a luciferase reporter vector (⌬Np63-luc), which was transiently transfected into TAZ-low SK-BR3 breast cancer cells alone or in combination with increasing dosages of TAZ (Fig. 2E). Concordant with our previous results, TAZ showed a dosage-dependent suppression of ⌬Np63-luc activity, suggesting that TAZ causes reduced ⌬Np63 expression by suppressing its promoter activity. Together, these results strongly suggest ⌬Np63 as a bona fide downstream target negatively regulated by TAZ in several breast and lung cell lines. TBD Is Necessary for TAZ-induced Negative Regulation of ⌬Np63-TAZ was originally identified as a transcriptional coactivator that lacks a DNA binding domain. Thus, to modulate transcription of downstream cellular genes, TAZ requires interactions with transcription factors through its TBD or WW (W, tryptophan) domain. Previous studies have shown that TAZ interacts with members of the TEAD family of transcription factors (TEAD1-4) through seven conserved residues in the TBD of TAZ (23,28). Among these, two phenylalanine residues located at positions 52 and 53 (Phe-52/53) were shown to be critical for TAZ-TEAD binding. Therefore, we examined whether the effect of TAZ on ⌬Np63 repression could be abolished in TBD mutants of TAZ. We generated a missense mutation in TAZ Phe-52 and Phe-53 residues (TAZ-F52A/F53A) to abolish TEAD interaction with TAZ. We then established MCF10A cells stably expressing TAZ-F52A/F53A and examined the effect of this TAZ mutant on mRNA and protein expression of ⌬Np63. qRT-PCR and Western blot analysis showed that loss of interaction with TEAD in TAZ-F52A/F53A mutant completely abolished TAZ-induced suppression of both protein and mRNA of ⌬Np63 (Fig. 3, A and B). The TAZ-F52A/F53A mutant also showed inability to suppress ⌬Np63 promoter activity (Fig. 3C). Interestingly, loss of interaction with TEAD in TAZ-F52A/F53A had a dominant-negative effect and activated transcription (1-28 Ϯ 0 -1-fold) of many down-regulated genes including ⌬Np63, BMP2, CXCL2, CXCL3, IL1␣, and IL1␤ (Fig. 3, B and D). Conversely, overexpression of TAZ-F52A/F53A can still suppress TAp63 mRNA, suggesting that TAZ regulates TAp63 and ⌬Np63 differently and that TAZ may down-regulate TAp63 independently of TEAD. Next, we sought to explore whether the TBD of TAZ was the only domain responsible for p63 suppression. Because the TAZ WW domain has been shown to be critical for gene transcription regulation through interaction with (L/P)PXY (L, lysine; P, proline; X, any amino acid; Y, tyrosine) motif-containing transcription factors such as TTF1 and Pax8 (36 -38), we tested whether a WW domain TAZ mutant (TAZ-WWm) containing two residue mutations, W152A and P155A, had any effect on TAZ-induced suppression of ⌬Np63.  the effect observed in MCF10A-TAZ-S89A, in the presence of Dox, the WW domain mutant TAZ-WWm effectively suppressed ⌬Np63 expression (Fig. 3A). Together, these findings suggest that the TBD, but not the WW domain, of TAZ is essential for TAZ-induced repression of ⌬Np63.
TEAD Is Essential for TAZ-induced Suppression of ⌬Np63-To directly confirm whether TAZ suppresses ⌬Np63 through TEAD, we performed transient knockdown of TEAD using a previously used siRNA simultaneously targeting TEAD1, TEAD3, and TEAD4 (siTEAD) in MCF10A cells with inducible expression of constitutively active TAZ-S89A. Although ⌬Np63 protein and mRNA were significantly repressed by TAZ-S89A in the presence of Dox in cells expressing a siRNA negative control (siCtrl), TAZ-S89A-mediated repression of ⌬Np63 seemed to be abolished in MCF10A cells with TEAD knockdown (Fig. 4, A and B). In addition, TEAD knockdown also diminished TAZ-induced suppression of ⌬Np63 promoter (Fig. 4C). Moreover, although TAZ can suppress ⌬Np63-luc activity in TEAD-positive SK-BR3 cells, its suppression on ⌬Np63 promoter was abolished in TEAD-negative SK-Luci6 lung cancer cells (Fig. 4, D and E). Together, these studies strongly suggest that TEAD is essential for TAZ-induced suppression of ⌬Np63.

JOURNAL OF BIOLOGICAL CHEMISTRY 16911
Modulation of Deacetylation Is Critical for TAZ-TEAD-induced Suppression of ⌬Np63-Two recent studies suggest that TEAD or its Drosophila homolog Scallop can suppress cellular gene transcription through interaction with transcription cofactor VGLL4 or Tgi, respectively (39,40). However, VGLL4 knockdown in MCF10A cells could not block TAZ-induced suppression of ⌬Np63 (Fig. 6, A and B), suggesting that VGLL4 is not involved in TAZ-TEAD-induced transcriptional repression of ⌬Np63.
Previous studies also suggest that transcriptional suppression of some genes may depend on DNA methylation or histone deacetylation of chromatin of their promoter regions (41)(42)(43). To explore whether TAZ-TEAD-induced ⌬Np63 transcriptional repression is due to chromosome methylation/ acetylation, we treated breast cancer cells with inhibitors of histone modification. Significantly, treatment of cells with histone deacetylase inhibitor trichostatin A rather than histone methyltransferase inhibitor UNC0631 partially rescued TAZinduced suppression of ⌬Np63 transcription (Fig. 6C). Moreover, we have further shown that TAZ directly interacts in vivo with some components (CHD4, MTA1, and RBP46) of the histone deacetylase complex (Fig. 6D).

Functional Implications of TAZ-TEAD Interactions and
⌬Np63 Suppression-Our results have strongly elucidated the role of TEAD and its co-activator TAZ in p63 transcriptional repression, particularly ⌬Np63, in breast and lung epithelial cells. Because TAZ overexpression has been previously correlated with enhanced cell migration and invasion (14,15,44) and ⌬Np63 knockdown causes EMT and increased cell migration and metastasis in MCF10A cells or breast cancer (45)(46)(47), we sought to elucidate the functional consequences of TAZ-TEAD-mediated repression of ⌬Np63 in breast cell migration. First, we reintroduced ⌬Np63 expression in MCF10A-TAZ cells by using lentiviral infection. Assessment of similar TAZ and ⌬Np63 protein expression levels was performed by Western blotting (Fig. 7A). Second, we sought to examine the functional implications of ⌬Np63 suppression on cell migration by performing a wound healing assay in MCF10A cells expressing WPI vector control, TAZ, or TAZ plus ⌬Np63. Cell migration was compared at different time points after wound induction. Compared with the WPI control (MCF10A-WPI), TAZ-overexpressing cells (MCF10A-TAZ) increased cell migration 9.0 Ϯ 1.5-and 8.8 Ϯ 3.5-fold at 20 and 40 h, respectively. However, this effect was partially FIGURE 5. TAZ and TEAD are recruited on ⌬Np63 promoter through TREs to directly suppress ⌬Np63 transcription. A, TEADs repress ⌬Np63 promoter activity. SK-BR3 cells were transfected with ⌬Np63-luc alone or in combination with TEAD1, TEAD2, TEAD3, or TEAD4, and luciferase assay was performed as described in Fig. 2E. B, ChIP analysis of TAZ interaction with the ⌬Np63 promoter. DNA and protein were cross-linked after treating MCF10A-WPI and MCF10A-TAZ-S89A-HA cells with 1% formaldehyde. Chromatin and DNA-binding protein were subjected to immunoprecipitation using mouse monoclonal ␣-HA (F7) antibody followed by PCR and electrophoresis on a 3% agarose gel. 0.2% input chromatin extracted from MCF10A-WPI or MCF10A-TAZ-S89A-HA cells was used as a positive PCR control. C, mapping the TRE in the ⌬Np63 promoter. Three potential TREs (TRE1 (GGAAT), TRE2 (CATGCC), and TRE3 (GGTAT)) in the ⌬Np63 promoter were mutated (TRE1M (AAAAA), TRE2M (AAAAAA), and TRE3M (AAAAA)) alone or in combination (TRE1/2M). ⌬Np63-luc containing WT, TRE1M, TRE2M, TRE3M, or TRE1/2M was transfected alone (ϪTAZ; control) or together with TAZ (ϩTAZ) into SK-BR3 cells followed by the Dual-Luciferase assay. Promoter activity is shown relative to control and was calculated as the ratio of relative luciferase units of ϩTAZ to ϪTAZ. abolished in TAZ-⌬Np63-expressing cells (MCF10A-TAZ-⌬Np63) (Fig. 7, B and C).
Interestingly, further examination of TAZ and its two domain mutants showed that although Dox induction of TAZ-S89A (ϩDox) caused increased cell migration TBD mutant TAZ-F52A/F53A completely abolished TAZ-induced increased cell migration in MCF10A cells (Figs. 3A and 7D). Conversely, WW domain mutant TAZ-WWm can still cause increased cell migration (Fig. 7D), suggesting that TEAD binding domain, rather than WW domain, is essential for TAZinduced increased cell migration. Furthermore, enhanced cell migration is also observed when TAZ-S89A is overexpressed in the presence of Dox (ϩDox) in HBE135 cells (Figs. 2C and 7E). Moreover, down-regulation of TAZ in A549 and HCC38 cells inhibits cell migration (Fig. 7F). Finally, we have further shown that overexpression of TAZ-S89A in both breast MCF10A and lung HBE135 cells causes EMT, thus suggesting that this TAZinduced increased cell migration is due to loss of cell-cell adhesion (Fig. 7, G and H). In summary, our results suggest that TAZ interacts with TEAD to promote ⌬Np63 suppression and reduced cell-cell adhesion, thus increasing the migratory capacity of cells, which can further lead to metastatic progression in breast and lung cancer cells.

Discussion
TAZ Is a Dual Regulator of Gene Transcription-Studies have widely characterized TAZ as a transcriptional co-activator of gene expression. Its ability to interact with a wide range of transcription factors accounts for its multifunctional effects in tumor development and progression. Moreover, TAZ-induced activation of protumorigenic genes such as Cyr61, CTGF, BMP4 (32,44) and many others has been often reported in the literature. However, our DNA microarray data have uncovered a whole new perspective on TAZ transcriptional regulation. Besides its well studied role as a transcriptional co-activator, our results have suggested a novel function of TAZ in transcriptional repression. This transcriptional duality of TAZ has been previously questioned after observing that TAZ-induced activation of RUNX2 and repression of the transcriptional activity of peroxisome proliferator-activated receptor-␥ were critical for mesenchymal stem cell differentiation (48). Recently, phosphorylation of Tyr-316 of TAZ has been shown to promote TAZ interaction and repression of the transcriptional activity of NFAT5 in response to hyperosmotic stress (49). Although these studies have shed light on the transcriptional repressing potential of TAZ, they have failed to elucidate the molecular mechanisms and oncogenic functions underlying TAZ-in-FIGURE 6. Suppression of ⌬Np63 transcription by TAZ through modulation of chromatin acetylation rather than VGLL4. A, knockdown of VGLL4 by siRNA. MCF10A-TAZ-S89A cells were transfected with control siRNA (siCtrl) or siRNA against VGLL4 (siVGLL4) followed by incubation in the absence (Ϫ) or presence (ϩ) of Dox for 1 day. Cells were subjected to protein extraction and Western blot analysis using anti-p63 and anti-VGLL4 antibodies. B, qRT-PCR analysis of ⌬Np63 mRNA. Experimental procedures were as described in A. C, levels of ⌬Np63 mRNA after treatment of cells with histone deacetylase (HDAC) and histone methyltransferase inhibitors. MCF10A-TAZ-S89A cells were untreated or treated with trichostatin A (TSA) (300 nM) or UNC0631 (20 M) in the absence (Ϫ) or presence (ϩ) of Dox for 1 day followed by qRT-PCR analysis. Data analysis was described in Fig. 1B. D, interaction of TAZ with histone deacetylase complex. Co-immunoprecipitation analysis was performed by immunoprecipitation (IP) of TAZ-HA in 250 g of protein lysates extracted from MCF10A-WPI and MCF10A-TAZ-S89A-HA cells using anti-HA antibody followed by Western blotting using each specific antibody against each protein of the histone deacetylase complex. The membrane was stripped and reprobed with anti-HA antibody to see whether TAZ-S89A-HA was pulled down from MCF10A-TAZ-S89A-HA rather than WPI cells. About 1 ⁄100 of input protein lysate (2.5 g) was also subjected to Western blotting. The experiment was performed in triplicate, and error bars represent S.D. from each set of triplicates. *, statistically significant difference (p Ͻ 0.05).
duced suppression. The fact that our microarray results have shown that transcription of over 320 cellular genes can be suppressed by TAZ has uncovered a new layer of the signaling complexity of TAZ and the Hippo pathway. Furthermore, validation analysis of several target genes including p63 and proinflammatory cytokines and chemokines has indeed confirmed that TAZ expression is also critical for transcriptional inhibition. Moreover, the strong repression of IL1␣/␤ exerted by TAZ has suggested a novel role in modulating the inflammatory response and tumor microenvironment. In fact, TAZ was found to indeed repress IL1␤ promoter in the same manner as shown for ⌬Np63 (data not shown). Collectively, our results have elucidated an underrated role of TAZ as a negative regulator of transcription in breast and lung epithelial cells. Moreover, we have uncovered the duality of TAZ in gene transcription regulation, a trait that has been reported previously for other transcriptional cofactors such as CCAAT-enhancerbinding protein or cAMP-response element-binding protein (CREB)-binding protein and its paralog p300 (50,51).
⌬Np63 Is a Novel Downstream Target Negatively Regulated by TAZ-Despite the progress made toward elucidating the molecular mechanisms involved in breast cancer development and progression, metastatic cancer cells remain a major obstacle for successful breast cancer treatments. In this context, TAZ has been highly associated with cell acquisition of EMT phenotypes and subsequent metastatic dissemination of breast cells (14,15,32,52). By regulating gene expression, TAZ has been shown to modulate oncogenic traits in cells. However, the transcriptional downstream targets mediating these TAZ-induced phenotypes remain mostly unexplored. By using a DNA microarray and real time qRT-PCR, we identified p63 isoforms TAp63 and ⌬Np63 as transcriptional targets negatively regulated by TAZ in mammary tumorigenesis. Of these, ⌬Np63 showed the most significant repression and was shown to be the predominant isoform expressed in MCF10A cells. Therefore, we characterized ⌬Np63 as a bona fide negative transcriptional target of TAZ involved in cell migration. First, we have shown that TAZ overexpression in MCF10A non-tumorigenic breast cells causes a significant decrease in ⌬Np63 mRNA expression levels (Fig. 1D). Second, we have shown that overexpression of both wild-type TAZ and its constitutively active mutant TAZ-S89A suppresses ⌬Np63 protein expression in MCF10A cells, whereas TAZ knockdown caused increased ⌬Np63 in breast and lung cancer cells (Fig. 2, A, B, and D). Finally, we have confirmed that TAZ physically interacts with ⌬Np63 promoter and causes ⌬Np63 transcriptional repression through interaction with TEAD and TRE (Fig. 2E).
After confirming that ⌬Np63 is indeed a real downstream target negatively regulated by TAZ, we examined the functional implications of ⌬Np63 down-regulation in mammary epithelial cells. After reintroducing ⌬Np63 protein expression into TAZoverexpressing MCF10A cells, we found that ⌬Np63 could par- tially reverse TAZ-mediated cell migration (Fig. 7, A-C). Specifically, assessment of the migration distance of MCF10A cells expressing TAZ plus ⌬Np63 showed a significantly slower wound closure rate that was more similar to that displayed by MCF10A-WPI control than by MCF10A-TAZ cells. Because multiple genes may regulate breast cancer cell migration, ⌬Np63 re-expression could not completely reverse this TAZmediated phenotype. Nonetheless, our studies strongly suggest that ⌬Np63 is one of the genes involved in TAZ-induced cell migration. These results are consistent with studies showing ⌬Np63 as an inhibitor of cell migration, invasion, and metastatic progression in breast cells (45,46). Moreover, p63 and particularly ⌬Np63 expression has been specifically observed in normal myoepithelial breast cells, has been proposed as a marker for cell differentiation, and is shown to be down-regulated in non-metaplastic invasive breast carcinomas (33,(53)(54)(55). Importantly, TAZ overexpression is highly correlated with breast cancer invasiveness and dissemination (32). Thus, it is likely that TAZ-induced suppression of ⌬Np63 enhances its metastatic potential by promoting EMT and breast cell migration. It will be interesting to further investigate the correlation between the levels of TAZ and ⌬Np63 and whether these could be used as prognostic biomarkers for clinical metastatic breast cancer. Until then, our results have provided a better understanding of the molecular mechanisms of TAZ-induced metastatic dissemination that might be critical for future development of effective targeted therapies for breast and lung cancer patients.
TEADs Are Critical Binding Partners of TAZ, Which Suppresses ⌬Np63 Transcription-Our results have identified the members of the TEAD/transcriptional enhancer factor family as major transcription factors mediating TAZ-induced transcriptional repression of downstream genes, particularly ⌬Np63. We showed that TAZ could no longer suppress ⌬Np63 promoter activity in TEAD-null SK-luci6 cells or MCF10A cells with TEAD knockdown (Fig. 4, D and E). This TAZ-TEADmediated suppression seems to be direct because our results have shown that TEAD itself can suppress ⌬Np63 promoter activity and that TAZ can suppress ⌬Np63 promoter activity by directly interacting with two TREs on the ⌬Np63 promoter (Fig. 5, B and C). Consistent with our findings, through ChIP sequencing, a recent study also suggests that TEAD2 can regulate EMT-relevant genes by acting as a transcriptional activator or repressor mainly by directly binding to the promoters containing TREs (56). It is still unclear why the same TAZ-TEAD complex activates transcription of some cellular genes such as CTGF and Cyr61 but suppresses transcription of other genes such as ⌬Np63. Most interestingly, several recent studies have identified components of the chromatin/chromatin-remodeling complexes (BRM, MED mediator complexes, and SWI/SNF complexes) and histone methyltransferase (Ncoa6) complexes as binding partners of TAZ or its Drosophila homolog Yki (41,(57)(58)(59). Because these complexes control transcriptional status (activation or inactivation) of a specific gene, the methylation or acetylation status of chromatin on the promoter regions of a specific gene may determine the transcriptional activation or suppression functions of the TAZ-TEAD complex. Indeed, our data further showed that TAZ can directly interact with histone deacetylation complex (Fig. 6D) and that inhibition of histone deacetylase partially releases TAZ-induced suppression of ⌬Np63 transcription by directly interacting with histone deacetylation complex (Fig. 6C), suggesting that TAZ may suppress gene transcription by activating histone deacetylation and histone deacetylase-mediated chromatin tightening.
Besides TEAD-dependent transcriptional suppression by TAZ, we also observed TEAD-independent suppression of some downstream genes such as TAp63 and GJA1 (Fig. 3D). In addition, a recent study reported a ZEB2-dependent suppression of ⌬Np63 promoter by YAP (TAZ paralog) during squamous transdifferentiation of lung epithelial cells (60). These studies suggest that TAZ, like YAP, may also suppress cellular gene transcription through interacting with other transcription factors. Nevertheless, our findings have shed light on the unanticipated complexity of the mechanisms underlying TAZ and TEAD interaction for gene transcriptional regulation and provide convincing evidence that TAZ can exert its function by negatively regulating transcription of downstream cellular genes such as ⌬Np63 through interaction with TEAD transcription factor.